All manuscripts
Publications VST Cells

AIM™ platform: A new immunotherapy approach for viral diseases

Published Journal Frontiers in Medicine

Share
14 pages AIMTM platform: A new immunotherapy approach for viral diseases — Frontiers in Medicine, 2022

Overview

This document describes the AIM platform's ability to enrich and expand antigen-specific CD8+ T cells for viral targets. G-Rex® culture systems were used for the 14-day expansion process.

What this paper found

AIM nanoparticles, which mimic dendritic cell function, enriched and expanded multi-antigen-specific CD8+ T cells against EBV, HTLV-1 and HPV from HLA-A*02:01 healthy-donor leukapheresis cells. CD8+ T cells were enriched on a CliniMACS Prodigy and expanded for 14 days in a G-Rex® culture system. Summed antigen-specific frequencies were 95.45% and 69.23% for EBV in two donors, and 46.69% and 17.64% for HTLV-1. Over 90% of expanded cells had memory phenotypes. EBV-specific cells were polyfunctional and killed peptide-pulsed target cells. In four NEXI-003 validation runs, cells were 96.82% ± 2.89% CD3+/CD4− and killed HPV-16- and HPV-18-positive HLA-A2 tumor lines, with no significant killing of autologous PBMCs.

Note: Preclinical study using healthy-donor cells restricted to HLA-A*02:01.

In summary, AIM technology represents a new scalable and cost-effective therapeutic platform that has the potential to cure viral diseases. — David Langan, Ruipeng Wang, Keshanti Tidwell, Selome Mitiku, Alison Farrell, Catrina Johnson, Adam Parks, Lauren Suarez, Shweta Jain, Sojung Kim, Kristi Jones, Mathias Oelke, Jerome Zeldis, Frontiers in Medicine

Study details

Authors
David Langan, Ruipeng Wang, Keshanti Tidwell, Selome Mitiku, Alison Farrell, Catrina Johnson, Adam Parks, Lauren Suarez, Shweta Jain, Sojung Kim, Kristi Jones, Mathias Oelke, Jerome Zeldis
Institution
NexImmune Inc., Gaithersburg, MD, United States
Journal
Frontiers in Medicine
Year
2022
PMID / PMC
PMID: 36619639 · PMC
Cell type(s)
VST Cells
Application area
Infectious disease · Solid tumor
Study phase
Preclinical

How G-Rex® was used

After CD4+ T cell depletion on day 0, CD8+ T cells were enriched on a CliniMACS Prodigy using AIM nanoparticles. The enriched cells were then seeded into a G-Rex® culture system and expanded for 14 days. Cells were collected on day 14 and frozen in liquid nitrogen until testing.

Explore related

Full citation

Langan D, Wang R, Tidwell K, et al. AIM™ platform: A new immunotherapy approach for viral diseases. Front Med (Lausanne). 2022;9:1070529.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →